Merck Fosamax
Executive Summary
Once-weekly formulation of alendronate approved Oct. 20 for the prevention and treatment of postmenopausal osteoporosis. The product will be available in 35 mg and 70 mg tablets (seven times the existing 5 mg and 10 mg once-daily doses). Merck's distribution of a 40 mg Fosamax formulation for Paget's disease exclusively through CVS ProCare will give the company some pricing flexibility with the new 35 mg formulation (1"The Pink Sheet" Sept. 4, p. 8). The sNDA was filed in December
You may also be interested in...
Merck Fosamax 40 mg Distribution Plan Leaves Room For Once-Weekly Agent
Merck's exclusive distribution program for patients receiving Fosamax 40 mg tablets for Paget's disease will give the company pricing flexibility when a once-weekly 35 mg formulation is approved for prevention of osteoporosis.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials